There's no denying it…Biobetters and Biosimilars are both here to stay. Each has its own merits and challenges, and it is up to the companies themselves to decide which strategy best complement their pipelines and resources. The final word? If you're developing biobeters, it had better be better! If you're developing biosimilars, it had better be faster!
2012 Sessions Included:
- Featured Presentations: Hear from William Strohl of Centocor, David Shen of Teva and Jens Vogel of Bayer on Development to Manufacturing of Biobetters, Biosimilars and Protein Drugs
- Beyond Half-Life Extension
- Extending Half-Life and Reducing Dosing Frequency
- Creating Biobetters with Enhanced Efficacy
- Improving Delivery through Enhanced Formulations
- Value Proposition of Biobetters vs. Biosimlars
- Quality Testing and Assay Development of Biobetters & Biosimilars
- Development of Biobetters/Biosimilars in China